Lexology January 16, 2025
On January 1, 2025, Amgen launched the first interchangeable biosimilar of Janssen / Johnson & Johnson’s Stelara® (ustekinumab), Wezlana™ (ustekinumab-auub), as a private label product through Optum Health’s Nuvaila. According to Optum’s formulary, Wezlana™ for Nuvaila will be available in low-wholesale acquisition cost (WAC) and high-WAC versions. Wezlana™’s interchangeability designation will allow pharmacies to switch patients without intervention from their prescriber, subject to state laws. Wezlana™ will be placed on the same formulary tier as Stelara®.
Along with this launch, Optum also updated its formulary with respect to Humira® (adalimumab) and its biosimilars. Previously Optum had offered Humira® along with Amgen’s Amjevita™ (adalimumab-atto), Boehringer Ingelheim’s Cyltezo® (adalimumab-adbm) and unbranded adalimumab-adbm, and Sandoz’s Hyrimoz® (adalimumab-adaz) and unbranded adalimumab-adaz. As of January...
Today's Sponsors
Today's Sponsor